“The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.

“The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.

If a compound is powerful enough to treat disease, alter metabolism, or change human physiology, it is powerful enough to harm.